$SLXN (Silexion Therapeutics) — 8-K: Silexion sets 1-for-24 reverse split effective November 10, 2026, to regain Nasdaq compliance

Silexion Therapeutics will combine every 24 ordinary shares into one, effective after market close on November 10, 2026, with split-adjusted trading beginning November 11, 2026, under ticker SLXN and new CUSIP G1281K163. Par value rises from $0.135 to $3.24 per share, and no fractional shares will be issued, with DTC participants entitled to fractions receiving a rounded-up whole share. The company said the split is intended to remedy its Nasdaq minimum bid price deficiency under Listing Rule 5550(a)(2) and support equity financings. Silexion also noted it dosed its first patient in September in the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.

Silexion Therapeutics will combine every 24 ordinary shares into one, effective after market close on November 10, 2026, with split-adjusted trading beginning November 11, 2026, under ticker SLXN and